ISC High Performance 2022: Liqid Introduces EMEA Attendees to Composable Disaggregated Infrastructure for a More Flexible, Sustainable Data Center
Liqid, the world’s leading software company delivering data center composability, announced today it is taking part in ISC High Performance 2022 (booth #B211), providing live demonstrations of the company’s Liqid Matrix™ composable disaggregated infrastructure (CDI) software. Dynamic infrastructure orchestration from Liqid delivers improved IT performance and agility for the most demanding next-gen applications such as artificial intelligence and machine learning (AI+ML), edge computing deployments, high-performance computing, and virtualization. Increased efficiency helps minimize the data center footprint, delivering software-defined ability to share resources no matter where they physically reside, making Liqid solutions fundamental to a more sustainable data center ecosystem. Available today for customers in the Europe, Middle East, & Africa (EMEA) region, solutions based on Liqid Matrix CDI software deliver architectural flexibility and efficiency to maximize time-to-value for high-value applications across industry verticals.
“AI applications, edge data center deployments reading multiple streams of sensor data, HPC-driven genomic research, and even more traditional software deployments like virtualization are taxing traditional data center infrastructures, increasingly making them neither practical nor sustainable,” said Paul Silver, Vice President and General Manager, EMEA, Liqid. “We’re excited to be able to bring our composable solutions to ISC High Performance attendees and the wider EMEA market to help better address the sea changes taking place in the data center ecosystems.”
Liqid Matrix software enables IT users to configure bare-metal servers in seconds. With Liqid Matrix, independent resource pools are orchestrated on-demand to instantly address the requirements of the specific workload. Once the workload is complete, resources are released back into the pool for use by other applications. This eliminates the need for costly overprovisioning of infrastructure, reduces power and cooling requirements, and enables the most efficient and sustainable data center architectures.
Liqid offers EMEA customers a cost-effective way to disaggregate and pool data center resources at large scale via software, across all industry-standard fabrics, for dynamically configurable, bare-metal servers. With composable disaggregated infrastructure solutions from Liqid, IT users can:
- Accelerate Time-to-Value: Dynamically configure servers in seconds to meet exacting workload requirements. Create configurations that aggregate the power of dozens of GPUs and other accelerators as required.
- Improve IT Agility: Scale resources like compute, networking, NVMe storage, GPU, FPGA, and storage-class memory beyond a server’s physical limitations, across all industry-standard fabrics, with just a couple of clicks; when data center devices are no longer needed, they are released back to the pool to be used by other applications. Leverage Liqid Command Center’s RESTful API and integrations with popular tools like Ansible to automate the provisioning of bare‐metal resources.
- Increase Efficiency: Only purchase resources when they’re needed. Extend the life cycle of existing IT server investments. Better manage costs associated with data center footprint with greater infrastructure utilization.
“Liqid is a company that offers a flexible, software-defined infrastructure designed to optimize the access and usage of high-value IT components. Liqid has worked to create what it called ‘composable disaggregated infrastructure’ that frees IT users from vendor lock-in and traditional purchasing cycles, enabling them to build a living data center architecture that changes to meet their business needs and scales as required,” wrote senior analyst Scott Sinclair and senior research analyst Moya Keane of Enterprise Strategy Group (ESG), a division of TechTarget, in a recent ESG Showcase. “A composable infrastructure provides significant improvements to performance, architectural optimization, hardware utilization issues, and, importantly, footprint efficiency—basically eliminating the urge to overprovision.”
To download ESG’s “Why IT Must Prioritize Sustainability,” go here. Schedule an appointment with an expert on solutions based on Liqid Matrix CDI software and set up a free infrastructure evaluation by going here. Follow Liqid on Twitter and LinkedIn to stay up to date with the latest Liqid news and industry insights.
About Liqid
Liqid’s composable infrastructure software platform, Liqid Matrix, unlocks cloud-like speed and flexibility plus higher efficiency from on-prem infrastructure. Now IT can configure, deploy, and scale physical, bare-metal servers in seconds, then reallocate valuable accelerator and storage resources via software as needs evolve. Dynamically provision previously impossible systems or scale existing investments, and then redeploy resources where needed in real-time. Unlock cloud-like datacenter agility at any scale and experience new levels of resource and operational efficiency with Liqid.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220529005033/en/
Contact information
Robert Brumfield
Sr. Director, Global Communications
Liqid
917 224 7769
brumfield.bob@liqid.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
4Moving Biotech Receives FDA IND Clearance for 4P004, Strengthening Its Position as a Leading Innovator in Disease-Modifying Osteoarthritis Therapeutics8.1.2026 08:30:00 EET | Press release
4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for 4P004, enabling the expansion of the Phase 2a INFLAM MOTION clinical trial into the United States (US). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107798042/en/ 4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for 4P004, enabling the expansion of the Phase 2a INFLAM MOTION clinical trial into the United States (US). The U.S. Food and Drug Administration (FDA) approval marks another strategic step in 4MB’s global clinical deployment across
Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo ® in France, Denmark, Iceland, Sweden, Finland and Norway8.1.2026 08:30:00 EET | Press release
Organon today announced that it has entered into an agreement with Daiichi Sankyo Europe to commercialize Nilemdo® (bempedoic acid) in France, Denmark, Iceland, Sweden, Finland and Norway. Nilemdo® is a new, first-in-class drug indicated for patients with high cholesterol and cardiovascular disease risk. It provides an alternative treatment for patients that cannot be treated effectively with statins.ii “This collaboration combines Organon’s commercial agility with Daiichi Sankyo’s expertise in cardiovascular innovation to bring Nilemdo® to patients in France, Denmark, Iceland, Sweden, Finland and Norway,” says Thibault Crosnier Leconte, AVP & Managing Director at Organon Northwest Europe. “By offering a new treatment option for patients who cannot tolerate statins, we are helping to close a persistent gap in cardiovascular care—one that disproportionately affects women – whilst reinforcing our mission to deliver impactful treatments for a healthier every day.” Cardiovascular disease i
Azafaros to Present at J.P. Morgan’s 44 th Annual Healthcare Conference8.1.2026 08:00:00 EET | Press release
Azafaros, a company building a portfolio to become a leader in lysosomal storage disorders with the goal of addressing neurological symptoms, today announced that it will present at J.P. Morgan’s 44th Annual Healthcare Conference on Thursday, January 15. The company’s presentation will begin at 9:30 am PT/12:30 am ET/6:30 am CET. The presentation will focus on the company’s lead product, nizubaglustat, a potential treatment for rare lysosomal storage disorders with neurological involvement including GM1/GM2 gangliosidoses and Niemann-Pick type C disease ((NPC). Two pivotal Phase 3 studies investigating nizubaglustat in GM1/GM2 gangliosidoses and NPC are currently enrolling, with data expected in 2027. The studies build on positive data from a robust clinical program including the Phase 2 RAINBOW study and the PRONTO natural history study. The Phase 3 studies are financed following the company’s successful completion of €132 million series B round completed in 1H 2025. About nizubaglust
Prodapt Earns ISO 42001 Certification, the New Global Benchmark for Responsible Enterprise AI8.1.2026 08:00:00 EET | Press release
Prodapt today announced that it has been awarded the ISO 42001 certification, the world’s first and the only global standard for AI Management Systems (AIMS). Marking a significant milestone in its journey, Prodapt is setting a higher benchmark to deliver secure, ethical, and scalable AI for global enterprises. ISO 42001 lays a rigorous framework for governing AI across strategy, technology, and operations. The certification, awarded by an independent accredited body, validates Prodapt’s enterprise-grade AI management framework, including executive-led oversight, strong technology foundations, and disciplined operational processes. These measures ensure AI systems are responsibly designed, deployed, monitored, and evolved throughout their lifecycle. The evaluation emphasizes risk management, ethical AI practices, transparency, and scalability, confirming Prodapt’s ability to proactively identify and mitigate risks while ensuring accountability in AI-driven outcomes. Human-in-the-loop c
Zilch to Acquire Fjord Bank to Kickstart European Expansion8.1.2026 02:40:00 EET | Press release
Zilch, the consumer payments platform powering the future of commerce, today announces it has signed an agreement to acquire AB Fjord Bank, a Lithuania-based bank with approx. $120M in total assets that is authorised and regulated by the Bank of Lithuania and the European Central Bank. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107714872/en/ Zilch to Acquire Fjord Bank to Kickstart European Expansion The acquisition will represent a major strategic milestone for Zilch, providing a European banking licence that will enable the accelerated rollout of its offering across Europe. Zilch will purchase 100% of Fjord Bank and will establish Lithuania as its European headquarters as a consequence of the transaction, using Vilnius as its operational and regulatory platform for expansion across Europe. Launched in 2021, Fjord Bank is a profitable and fully regulated challenger bank, focusing on online consumer lending and saving
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom